New antithrombotic drugs on the horizon

Bibliography

• MURRAY CJ, LOPEZ AD: Mortalitiy bycause for eight regions of the world; global burden of disease study. Lancet (1997) 349:1269–1276.
   PubMed Web of Science ®Google Scholar
• ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. (2002) 324:71–86.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the importance of aspirin for prevention.
   Google Scholar
• NEWBY LK, MCGUIRE DK: Oral platelet glycoprotein IIb/IIIa inhibition. Carr. Cardiol Rep. (2000) 2:372–377.
   PubMedGoogle Scholar
• TURPIE AG: Optimizing prophylaxis of venous thromboembolism. &min. Thromb. Hemost. (2002) 28\(Suppl. 2):25–32.
   Google Scholar
• DAVIE EW, FUJIKAWA K, KISIEL W: The coagulation cascade: initiation, maintenance, and regulation. Biochemistry (1991) 30:10363–10370.
   PubMed Web of Science ®Google Scholar
• •Good overview on the coagulation cascade.
   Google Scholar
• MUTCH NJ, ROBBIE LA, BOOTH NA: Human thrombi contain an abundance of active thrombin. Thromb. Haemost. (2001) 86:1028–1034.
   PubMed Web of Science ®Google Scholar
• EZEKOWITZ MD, NETREBKO PI: Anticoagulation in management of atrial fibrillation. Can: Opin. Cardiol (2003) 18:26–31.
   PubMed Web of Science ®Google Scholar
• VLASUK GP: Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation Factor Xa. Thromb. Haemost. (1993) 70:212–216.
   PubMed Web of Science ®Google Scholar
• TUSZYNSKI GP, GASIC TB, GASIC GJ: Isolation and characterization of antistasin. Biol Chem. (1987) 262:9718–9723.
   Web of Science ®Google Scholar
• RIVERA TM: Oral delivery of heparin in combination with sodium N-(8[2-hydroxybenzoyl] amino)caprylate: pharmacologic considerations. Pharm. Res. (1997) 14:1830–1834.
   PubMed Web of Science ®Google Scholar
• MALKOV D, WANG HZ, DINH S, GOMEZ-ORELLANA I: Pathway of oral absorption of heparin with sodium N- [842-hydroxybenzoyl)amino] caprylate. Pharm. Res. (2002) 19:1180–1184.
   PubMed Web of Science ®Google Scholar
• PINEO GE HULL RD, MARDER VJ: Orally active heparin and low-molecular-weight heparin. Curt: Opin. Palm. Med. (2001) 7:344–8.
   PubMedGoogle Scholar
• GONZE MD, SALARTASH K, STERNBERGH WC 3rd, BAUGHMAN RA, LEONE-BAY A, MONEY SR: Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation (2000) 101:2658–2661.
   PubMed Web of Science ®Google Scholar
• ANDERSON JA, FREDENBURGH JC, STAFFORD AR et al.: Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase..1. Biol. Chem. (2001) 276:9755–9761.
   Google Scholar
• FREDENBURGH JC, ANDERSON JA, WEITZ JI: Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin. Trends Cardiovasc. Med. (2002) 12:281–287.
   PubMed Web of Science ®Google Scholar
• SUNDARAM M, QI Y, SHRIVER Z, LIU D et al.: Rational design of low-molecular-weight heparins with improved in vivo activity. Proc. Natl. Acad. Set. USA (2003) 100:651–656.
   PubMed Web of Science ®Google Scholar
• CHOAY J, PETITOU M, LORMEAUJC, SINAY P, CASU B, GATTI G: Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem. Biophys. Res. Commun. (1983) 116:492–499.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BI, BAUER KA, LASSEN MR et al.: Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl. I Med. (2001) 345:1298–1304.
   PubMed Web of Science ®Google Scholar
• •Important clinical trial on the effect of pentasaccharide in orthopaedic surgery.
   Google Scholar
• TURPIE AGG, BAUER KA, ERIKSSON BJ et al.: Postoperative fondaparinux versus postoperative enoxaparin for the prevention of venous thromboembolism after elective hip-replacemetn surgery: a randomised double-blind trial. Lancet (2002) 359:1721–1726.
   PubMed Web of Science ®Google Scholar
• THE REMBRANDT INVESTIGATORS: Treatment of proximal deep vein thrombosis with a novel synthetic compound (5R90107A/ORG31540) with pure anti-factor Xa activity. Circulation (2000) 102:2726–2731.
   PubMed Web of Science ®Google Scholar
• VAN DE WERF F: New data in treatment of acute coronary syndromes. Am. Heart J. (2001) 142\(Suppl. 2):516–521.
   Google Scholar
• BAUER KA: Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin. Thromb. Hemost. (2002) 28\(Suppl. 2):15–24.
   Google Scholar
• •Good review on current and potential future antithrombotics.
   Google Scholar
• WALENGA JM, JESKE WP, FRAPAISE FX, BICK RL, FAREED J, SAMAMA MM: Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin. Investig. Drugs (2002) 11:397–407.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, HERAULT JP, BERNAT A et al: Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood (1998) 91:4197–4205.
   PubMed Web of Science ®Google Scholar
• REITER M, BUCEK RA, KOCA N, HEGER J, MINAR E: Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagul. Fibrinolysis (2003) 14:61–65.
   PubMed Web of Science ®Google Scholar
• HERAULT JP, BERNAT A, ROYE F et al:Pharmacolkinetics of new synthetic heparin mimetics. Thromb. Haemost. (2002) 87:985–989.
   PubMed Web of Science ®Google Scholar
• HERAULT JP, BERNAT A, GAICH C, HERBERT M: Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Thromb. Haemost. (2002) 87:238–244.
   PubMed Web of Science ®Google Scholar
• PORCARI AR, CHI L, LEADLEY R: Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors. Expert Opin. Investig. Drugs (2000) 9:1595–1600.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, BERNAT A, DOL F, HERAULT JP, CREPON B, LORMEAU JC: DX 9065a a novel, synthetic, selective and orally active inhibitor of Factor Xa: in vitro and in vivo studies. Pharmacol. Exp. The]: (1996) 276:1030–1038.
   Google Scholar
• MURAYAMA N, MCMAHON H, YOUNG CG et al.: Pharmacolkinetics of the anticoagulant 14C-DX-9065a in the healthy male volunteer after a single intravenous dose. Xenobiotica (2000) 30:515–521.
   PubMed Web of Science ®Google Scholar
• BECKER RC, YOUFU L, ALEXANDER JH, SPENCER F, ROBERTSON TL, KUNITADA S: DX-9065a, a novel direct Factor Xa antagonist stimulates release of tissue factor pathway inhibitor (TFPI) from human vascular endothelial cells. Circulation (2002) (Suppl. II):337 (Abstract).
   Google Scholar
• SHIMBO D, OSENDE J, CHEN J et al.: Antithrombotic effects of DX-9065a, a direct Factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb. Haemost. (2002) 88:733–738.
   PubMed Web of Science ®Google Scholar
• DYKE CK, BECKER RC, KLEIMAN NS et al.: First experience with direct Factor Xa inhibition in patients with stable coronary disease: a pharmacolkinetic and pharmacodynamic evaluation. Circulation (2002) 105:2385–2391.
   PubMed Web of Science ®Google Scholar
• PINTO DJ, ORWAT MJ, WANG S et al:Discovery of 143-(aminomethyl)phenyll-N-3-fluoro-2'-(methylsulfony1)-[1,1'biphenyl] 4 yl] 3 (trifluoromathyl)-1 pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation Factor Xa. Med. Chem. (2001) 44:566–578.
   Web of Science ®Google Scholar
• WONG PC, PINTO DJ, KNABB RM: Nonpeptide Factor Xa inhibitors: DPC423, a highly potent an orally bioavailable pyrazole antithrombotic agent. Cardiovasc. Drug Rev (2002) 20:137–152.
   PubMedGoogle Scholar
• WONG PC, CRAIN EJ, WATSON CA et al: Nonpeptide Factor Xa inhibitors III: Effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. Pharmacol. Exp. The]: (2002) 303:993–1000.
   Google Scholar
• CHU V, BROWN K, COLUSSI D et al.: Pharmacological characterization of a novel Factor Xa inhibitor FXV673. Thromb. Res. (2001) 103:309–324.
   PubMed Web of Science ®Google Scholar
• GUERTIN KR, GARDNER CJ, KLEIN SI et al.: Optimization of the beta-aminoester class of Factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent in vivo anticoagulant activity. Bioorg. Med. Chem. Lett. (2002) 12:1671–1674.
   Google Scholar
• REBELLO SS, BENTLEY RG, MORGAN SR et at: Antithrombotic efficacy of a novel Factor Xa inhibitor, FXV6 in a canine model of coronary artery thrombolysis. Br. Pharmacol. (2001) 133:1190–1198.
   PubMed Web of Science ®Google Scholar
• AHMED T: IDDB meeting report from the 17th International Society of Thrombosis and Haemostasis Congress 1999, Washington DC, USA. IDdb3 Report (1999) (338793).
   Google Scholar
• CHU V, BROWN K, COLUSSI D et al.: In vitro characterization of a novel Factor Xa inhibitor, RPR 130737. Thromb. Res. (2000) 99:71–82.
   PubMed Web of Science ®Google Scholar
• LIGHT DR, GUILFORD WJ: Discovery of the Factor Xa inhibitor, ZK 807834 (CI-1031). Carr. Top. Med. Chem. (2001) 1:121–136.
   PubMedGoogle Scholar
• CHI L, PEN YVV, POTOCZAK R et al.:Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct Factor Xa inhibitor. Pharmacology (2002) 64:76–83.
   PubMed Web of Science ®Google Scholar
• POST JM, SULLIVAN ME, ABENDSCHEIN D, EWING J, HINCHMAN JW, LIGL DR: Human in vitro pharmacodynamic profile of the selective Factor Xa inhibitor ZK-807834 (CI-1031). Thromb. Res. (2002) 105:347–352.
   PubMed Web of Science ®Google Scholar
• WONG PC, CRAIN EJ, KNABB RM et al.: Nonpeptide Factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.' Pharmacol. Exp. Ther. (2000) 295:212–218.
   Google Scholar
• WONG PC, QUAN ML, CRAIN EJ, WATSON CA, WEXLER RR, KNABB RM: Nonpeptide Factor Xa inhibitors: I. Studies with SF303 and 5K549, a new class of potent antithrombotics. I Pharmacol. Exp. Ther. (2000) 292:351–357.
   Google Scholar
• NARASIMHAN S, KOSKI RA, BEAULIEU B et al.: A novel family of anticoagulants from the saliva of Ixodes scapularis. Insect Mol. Biol. (2002) 11:641–650.
   PubMed Web of Science ®Google Scholar
• NISHIDA H, MIYAZAKI Y, MUKAIHIRA T et al.: Synthesis and evaluation of 1-arylsulfony1-3-piperazinone derivatives as a Factor Xa inhibitor II. Substituent effect on biological activities. Chem. Pharm. Bull. (2002) 50:1187–1194.
   PubMed Web of Science ®Google Scholar
• HIRAYAMA F, KOSHIO H, KATAYAMA N et al.: The discovery of YM-60828: a potent, selective and orally- bioavailable Factor Xa inhibitor. Bioorg. Med. Chem. (2002) 10:1509–1523.
   PubMed Web of Science ®Google Scholar
• SEMPLE JE, LEVY OE, MINAMI NK, OWENS TD, SIEV DV: Novel, potent and selective chimeric FXa inhibitors featuring hydrophobic Pi-ketoamide moieties. Bioorg. Med. Chem. Lett. (2000) 10:2305–2309.
   PubMed Web of Science ®Google Scholar
• HAYASHI M, MATSUO A, NAKAMOTO H, AISAKA K: Antithrombotic effects of a synthetic inhibitor of activated Factor X, JTV-803, in animals. Ear: Pharmacol. (2001) 412:61–66.
   PubMed Web of Science ®Google Scholar
• WATERWORTH C: IDDB meeting report from the XIVth Annual World Congress of Pharmacology; July 2002, San Francisco, USA. IDdb..? Report (2002) (457377).
   Google Scholar
• The IDdb reference report (460177): New drugs in the R&D pipeline. Pharma Japan (2002) 1806:1–20.
   Google Scholar
• SONG Y, CLIZBE L, BHAKTA C et al.: Design and synthesis of Factor Xa inhibitors and their prodrugs. Bioorg. Med. Chem. Lett. (2003) 13:297–300.
   PubMed Web of Science ®Google Scholar
• KAPLAN KL, FRANCIS CW: Direct thrombin inhibitors. Semin. Hematol. (2002) 39:187–196.
   PubMed Web of Science ®Google Scholar
• MATSUO T, KARIO K, KODAMA K, OKAMOTO S: Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805). Sem. Thromb. Hemost. (1992) 18:155–160.
   PubMed Web of Science ®Google Scholar
• HAUPTMANN J: Pharmacokinetics of anemerging new class of anticoagulant-antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eui: I Clin. Pharmacol. (2002) 57:751–758.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review on small molecular thrombin inhibitors.
   Google Scholar
• GLYNN 0: The express study: preliminaryresults. hat. Gin. Piaci (2003) 57:57–59.
   Google Scholar
• ERIKSSON BI, BERGQVIST D, KALEBO P et al.: Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet (2002) 360:1441–1447.
   PubMed Web of Science ®Google Scholar
• •Important clinical trial on the effect of xinctelagatranimelagatran in orthopaedic surgery.
   Google Scholar
• WAHLANDER K, LAPIDUS L, OLSSON CG et al.: Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb. Res. (2002) 107:93–99.
   PubMed Web of Science ®Google Scholar
• NOTEBERG D, BRANALT J, KVARNSTROM I et al.: New proline mimetics: synthesis of thrombin inhibitors incorporating cyclopentane- and cyclopentenedicarboxylic acid templates in the P2 position. j Med. Chem. (2000) 43:1705–1713.
   PubMed Web of Science ®Google Scholar
• HAUEL NH, NAR H, PRIEPKE H, RIES U, STASSEN JM, WIENEN W: Structure-based design of novel potent nonpeptide thrombin inhibitors. I Med. Chem. (2002) 45:1757–1766.
   PubMed Web of Science ®Google Scholar
• MUNGALL D: BIBR-1048 Boehringer Ingelheim. Carr. Opin. Investig. Drugs (2002) 3:905–907.
   PubMedGoogle Scholar
• BUCKLE DR: IDdb meeting report from the IXth RSC-SCI Medicinal Chemistry Symposium 1997, Cambridge, UK. IDdb..? Report (1997) (263572).
   Google Scholar
• KAKKAR S: New advances in a rapidly expanding blockbuster market. SMI Conference - Advances in Hypertension and Cardiovascular Therapeutics. IDdb..? Report (2002) (453507).
   Google Scholar
• 3-Dimensional Pharmaceuticals, Inc. IDdb..? Report (2001) (Press release, 399111).
   Google Scholar
• CHI L, MERTZ TE, ROGERS KL et al: Antithrombotic effect of LB-30057 (CI-1029), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran. Thromb. Thrombolysis (2001) 11:19–31.
   PubMed Web of Science ®Google Scholar
• McCLANAHAN TB, HICKS GW, IGNASIAK DP et al.: The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis. Thromb. Thrombolysis (2000) 10:277–284.
   PubMed Web of Science ®Google Scholar
• BERRY CN, LASSALLE G, LUNVEN C et al: 55R182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity. Pharmacol. Exp. The]: (2002) 303:1189–1198.
   Google Scholar
• GIARDINO EC, COSTANZO MJ, KAUFFMAN JA, LI QS, MARYANOFF BE, ANDRADE-GODRON P: Antithrombotic properties of RWJ-50353, a potent and novel thrombin inhibitor. Thromb. Res. (2000) 98:83–93.
   PubMed Web of Science ®Google Scholar
• ADANG AE, DE MAN AP, VOGEL GM et al: Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics. Med. Chem. (2002) 45:4419–4432.
   Web of Science ®Google Scholar
• NORMAN P: IDDB meeting report fromthe Cutting Edge Approaches to Drug Design - RSC's Second Meeting, London, UK, 2002. IDdb3 Report (2002) (444796).
   Google Scholar
• BRADY SF, STAUFFER KJ, LUMMA WC et al.: Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl-trans-4-aminocyclohexylmethyl amide (L-372, 460: coapplication of structure-based design and rapid multiple analogue synthesis on solid support. J. Med. Chem. (1998) 41:401–406.
   PubMed Web of Science ®Google Scholar
• BRUNDISH D, BULL A, DONOVAN V et al.: Design and synthesis of thrombin inhibitors: analogues of MD 805 with reduced stereogenicity and improved potency. " Med. Chem. (1999) 42:4584–4603.
   Google Scholar
• CUI JJ, ARALDI GL, REINER JE et al: Non-covalent thrombin inhibitors featuring P3-heterocycles with Pi-bycyclic arginine surrogates. Bioorg. Med. Chem. Lett. (2002) 12:2925–2930.
   PubMed Web of Science ®Google Scholar
• Servier, following the XVIIIth ISTH meeting 2001, Paris, France. IDdb.? Report (2001) (Press release, 415369).
   Google Scholar
• VitaResc Biotech AG. IDdb.? Report (2001) (Press release, 417532).
   Google Scholar
• FRIEDERICH PW, KELLER TT, BIEMOND BJ et al: Successful attenuation of venous thrombus growth in rabbits after the administration of a novel oral thrombin inhibitor. Thromb. Haemost. (2000) 84:858–864.
   PubMed Web of Science ®Google Scholar
• Groupe Fournier. IDdb.? Report (1999) (Company comm., 347216).
   Google Scholar
• GIRARD TJ, NICHOLSON NS: The role of tissue factor/factor VIIa in the pathophysiology of acute thrombotic formation. Curr. Opin. Pharmacol (2001) 1:159–163.
   PubMedGoogle Scholar
• BAJAJ MS, BAJAJ SP: Tissue factor pathway inhibitor: potential therapeutic applications. Thromb. Haemost. (1997) 78:471–477.
   PubMed Web of Science ®Google Scholar
• •Interesting review onTF and its potential therapeutic potential.
   Google Scholar
• PEDERSON AH, NORDFANG 0, NORRIS F et al.: Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor initiated coagulation reactions. J. Biol. Chem. (1990) 265:16786–16793.
   Google Scholar
• KAMIKUBO Y, HAMURO T, MATSUDA J et al.: Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: concerted effect with antithrombin. Thromb. Haemost. (1996) 76:621–626.
   PubMed Web of Science ®Google Scholar
• ROQUE M, REIS ED, FUSTER V et al.: Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty.' Am. Coll. Cardiol (2000) 36:2303–2310.
   PubMed Web of Science ®Google Scholar
• YANG J, LEE GE RIEDERER MA, KELLEY RF: Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to Factor VIIa. Thromb. Haemost. (2002) 87:450–458.
   PubMed Web of Science ®Google Scholar
• HIMBER J, REFINO CJ, BURCKLEN L, ROUX S, KIRCHHOFER D: Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig. Thromb. Haemost. (2001) 85:475–481.
   PubMed Web of Science ®Google Scholar
• KITAZAWA T, ASADA Y, KUMAGAI E et al.: Humanized anti-human tissue factor antibody prevents both arterial and venous thrombosis in non-human primates. Circulation (2002) (Suppl. (Abstract).
   Google Scholar
• DENNIS MS, EIGENBROT C, SKELTON NJ et al.: Peptide exosite inhibitors of Factor VIIa as anticoagulants. Nature (2000) 404:465–470.
   PubMed Web of Science ®Google Scholar
• DENNIS MS, ROBERGE M, QUAN C, LAZARUS RA: Selection and characterization of a new class of peptide exosite inhibitors of coagulation Factor VIIa. Biochemistry (2001) 40:9513–9521.
   PubMed Web of Science ®Google Scholar
• DUGGAN BM, DYSON HJ, WRIGHT PE: Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2. Eur.j Biochem. (1999) 265:539–548.
   PubMedGoogle Scholar
• BUDDAI SK, TOULOKHONOVA L, BERGUM PW, VLASUK GP, KRISHNASWAMY S: Nematode anticoagulant protein c2 reveals a site on Factor Xa that is important for macromolecular substrate binding to human prothrombinase." Biol. Chem. (2002) 277:26689–26698.
   PubMed Web of Science ®Google Scholar
• LEE A, AGNELLI G, BULLER H et al:Dose-response study of recombinant Factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation (2001) 3:74–78.
   Google Scholar
• CORVAS INTERNATIONAL CORP: NAPc2 safe and well tolerated in a Phase Ha PTCA trial. IDdb.? Report (2001) (Press release, 432360).
   Google Scholar
• RAI R, KOLESNIKOV A, YOUNG WB, SHRADER WD, LIU L, ENRIQUEZ P: Synthesis and pharmacokinetics of novel anticoagulants. 224' American Chemical Society Conference, Boston, MA, USA (2000).
   Google Scholar
• TAKEHANA S, KAYAHARA T, TASHIRO K et al: Antithrombotic effects of AXC4845, a newly synthezised and selective Factor VIIa inhibitor, in the rat thrombosis models. Thromb. Haemost. (2001) 86 (Suppl.): P1393 (Abstract).
   Google Scholar
• SO L: IDDB meeting report from the XVIIIth ISTH meeting 2001, Paris, France. IDdb Report (2001) (415130).
   Google Scholar
• HUBER K: Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic clisease.j Thromb. Thrombolysis (2001) 11:183–193.
   PubMed Web of Science ®Google Scholar
• •Good review on the role of PAT-1 in thromboembolic disease.
   Google Scholar
• YAMADA Y, IZAWA H, ICHIHARA S et al: Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl. Med. (2002) 347:1916–1923.
   PubMed Web of Science ®Google Scholar
• •Important study on the correlation of gene polymorphisms with myocardial infarction.
   Google Scholar
• CHARLTON PA, FAINT RW, BENT F et al: Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb. Haemost. (1996) 75:808–815.
   PubMed Web of Science ®Google Scholar
• RUPIN A, MARTIN F, VALLEZ MO, BONHOMME E, VERBEUREN TJ: Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of platelet-rich thrombus in rat mesenteric arterioles. Thromb. Haemost. (2001) 86:1528–1531.
   PubMed Web of Science ®Google Scholar
• MOHRI M, SUGIMOTO E, SATA M, ASANO T: The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation - a comparison with other anticoagulants. Thromb. Haemost. (1999) 82:1687–1693.
   PubMed Web of Science ®Google Scholar
• GRIFFIN JH, ZLOKOVIC B, FERNANDEZ JA: Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin. Hematol. (2002) 39:197–205.
   PubMed Web of Science ®Google Scholar
• JACKSON CV, BAILEY BD, SHETLER TJ: Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis.j Pharmacol. Exp. The]: (2000) 295:967–971.
   Google Scholar
• SAKAMOTO T, OGAWA H, TAKAZOE K et al.: Effects of human plasma-derived activated protein C on thrombolytic therapy in patients with acute myocardial infarction; comparison with unfractionated heparin. Circulation (2002) (Suppl. II):3104 (Abstract).
   Google Scholar
• SINGH I, SMITH A, VANZIELEGHEM B et al: Antithrombotic effects of controlled inhibition of Factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood(2002) 99:3235–3240.
   PubMed Web of Science ®Google Scholar
• CURACYTE AG. IDdb.? Report (Press release, 458876).
   Google Scholar
• WALL D, DOUGLAS S, FERROV, COWDEN W, PARISH C: Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides. Thromb. Res. (2001) 103:325–335.
   PubMed Web of Science ®Google Scholar
• DEMIR M, IQBAL 0, HOPPENSTEADT PA et al: Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin. Appl. Thromb. Hemost. (2001) 7:131–140.
   PubMed Web of Science ®Google Scholar
• RUEF J, PETER K, NORDT TK, RUNGE MS, KUBLER W, BODE C: Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb. Haemost. (1999) 82\(Suppl. 1):32–37.
   Google Scholar
• BURGAUD JL, ONGINI E, DEL SOLDATO P: Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann. NY Acad. Sci. (2002) 962:360–371.
   PubMed Web of Science ®Google Scholar
• •Interesting review on NO-releasing drugs.
   Google Scholar
• NicOx SA, on drug development pipeline (NCX-5022). IDdb..? Report (2002) (Company Comm., 453178).
   Google Scholar
• HOWARD PA: Aspirin resistance. Ann. Pharmacother: (2002) 36:1620–1624.
   Google Scholar
• PIENIASZEK I-1J Jr, SY SK, EBLING W et al.: Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. Clin. Pharmacol. (2002) 42:738–753.
   Google Scholar
• SEREBRUANY VL, MALININ Al, O'CONNOR CM, GURBEL PA: Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease. Circulation (2002) (Suppl. II):2436 (Abstract).
   Google Scholar
• DAMIANO BP, MITCHELL JA, GIARDINO E et al.: Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. Thromb. Res. (2001) 104:113–126.
   PubMed Web of Science ®Google Scholar
• SCHWARZ M, ROETTGEN P, LITTLE M et al.: Generation of human, activation-specific single chain antibodies directed against platelet integrin receptor GPIIb/IIIa. Circulation (2002) (Suppl. II):390 (Abstract).
   Google Scholar
• KAGEYAMA S, YAMAMOTO H, YOSHIMOTO R: Anti-human von Willebrand factor monoclonal antibody AjvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs. Arteriosclec Thromb. Vasc. Biol. (2000) 20:2303–2308.
   PubMed Web of Science ®Google Scholar
• KAGEYAMA S, MATSUSHITA J, YAMAMOTO H: Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur. Pharmacol. (2002) 443:143–149.
   PubMed Web of Science ®Google Scholar
• GUREVITZ 0, ELDAR M, SKUTELSKY E etal: 5-nitrosoderivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model. Thromb. Haemost. (2000) 84:912–917.
   PubMed Web of Science ®Google Scholar
• NIESWANDT B, SCHULTE V, BERGMEIER W et al.: Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. Exp. Med. (2001) 193:459–469.
   PubMed Web of Science ®Google Scholar
• SUGIDACHI A, ASAI F, YONEDA K et al.: Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br.Pharmacol. (2001) 132:47–54.
   PubMed Web of Science ®Google Scholar
• GOTO S, TAMURA N, ETO K, IKEDA Y, HANDA S: Functional significance of adenosine 5'-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation (2002) 105:2531–2536.
   PubMed Web of Science ®Google Scholar
• SCARBOROUGH RM, LAIBELMAN AM, CLIZBE LA et al.: Novel tricyclic benzothiazolo[2,3-c]thiadiazine antagonists of the platelet ADP receptor (P2Y(12)). Bioorg. Med. Chem. Lett. (2001) 11:1805–1808.
   PubMed Web of Science ®Google Scholar
• BAURAND A, RABOISSON P, FREUND M et al.: Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eui: Pharmacol. (2001) 412:213–221.
   PubMed Web of Science ®Google Scholar
• ANDRADE-GORDON P, MARYANOFF BE, DERIAN CK et al.: Design, synthesis, and biological characterization of a peptide mimetic antagonist for a tethered-ligand receptor. Proc. Nati Acad. Sci. USA (1999) 96:12257–12262.
   PubMed Web of Science ®Google Scholar
• COVIC L, MISRA M, BADAR J, SINGH C, KULIOPULOS A: Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. (2002) 8:1161–1165.
   PubMed Web of Science ®Google Scholar
• PRIETO AR, MA H, HUANG R et al.: Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury. Cardiovasc. Res. (2002) 53:984–992.
   PubMed Web of Science ®Google Scholar
• MOMI S, EMERSON M, PAUL W et al: Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Ear: j Pharmacol. (2000) 397:177–185.
   PubMed Web of Science ®Google Scholar
• FIORUCCI S, MENCARELLI A, MENEGUZZI A et al.: NCX-4016(NO-Aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo. Circulation (2002) 106:3120–3125.
   PubMed Web of Science ®Google Scholar
• GUREVICH VS, LOMINADZE DG, ADEAGBO AS et al.: Antithrombotic and vasorelaxant properties of a novel synthetic RGD peptide containing nitric oxide. Pharmacology (1997) 55:1–9.
   PubMed Web of Science ®Google Scholar
• GRESELE P, AGNELLI G: Novel approaches to the treatment of thrombosis. Trends Pharmacol. Sci. (2002) 23:25–32.
   PubMed Web of Science ®Google Scholar
• VAN AKEN H, BODE C, DARIUS H et al: Anticoagulation: the present and future. Chn. Appl Thromb. Hemost. (2001) 7:195–204.
   PubMed Web of Science ®Google Scholar
• WEITZ JI, HIRSH J: New anticoagulant drugs. Chest (2001) 119(Suppl.):95S–107S.
   Google Scholar
• •Excellent review on anticoagulant drugs.
   Google Scholar
• PATRONO C, RENDA G: Platelet activation and inhibition in unstable coronary syndromes. Am. Cardial (1997) 80:E17–E20.
   Web of Science ®Google Scholar
• VAN ES RF, JONKER JJ, VERHEUGT FW, DECKERS JW, GROBBEE DE: Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet (2002) 360:109–113.
   PubMed Web of Science ®Google Scholar
• LENZ TL, HILLEMAN DE: Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann. Pharmacother: (2000) 34:1283–1290.
   PubMed Web of Science ®Google Scholar
• READ ML, FARROW PJ, SEYMOUR LW: Emerging developments in RNA therapeutics. Exp. Opin. Ther. Targets (2003) 7:299–303
   PubMed Web of Science ®Google Scholar